Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL7670890 | 0.89 | LMNA (0.52) | LMNAMEN1CYP1A2KMT2AFDPS | |
| SCHEMBL2045705 | 0.82 | LMNA (0.50) | LMNAMEN1CYP1A2KMT2AFDPS | |
| SCHEMBL2518475 | 0.82 | LMNA (0.50) | LMNAMEN1CYP1A2KMT2AFDPS | |
| Methyl Alcohol SCHEMBL5434659 | 0.82 | LMNA (0.86) | LMNATHRBTSHR | |
| SCHEMBL2094168 | 0.82 | LMNA (1.00) | LMNATHRB | |
| SCHEMBL9459 | 0.82 | — | — | |
| Phosphoric Acid SCHEMBL16324558 | 0.81 | LMNA (0.41) | LMNAMEN1CYP1A2KMT2AFDPS | |
| Acetone SCHEMBL590699 | 0.80 | LMNA (0.71) | LMNATHRBTSHRALDH1A1TDP1 | |
| Bicarbonate SCHEMBL5374586 | 0.80 | LMNA (0.71) | LMNATHRBALDH1A1 | |
| Bicarbonate SCHEMBL28942687 | 0.80 | LMNA (0.71) | LMNATHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3954370-B1 | ANTI-FUNGAL AGENT | SEREN PHARMACEUTICALS INC (JP) | 2024-05-29 | — | — | EP | claimed |
| EP-1948665-B1 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-27 | — | — | EP | claimed |
| US-7989433-B2 | Substituted thieno[3,2-D]pyrimidines as melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-02 | — | — | US | claimed |
| EP-2310394-A1 | HYDROXY SUBSTITUTED THIENO PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2011-04-20 | — | — | EP | claimed |
| WO-2009146365-A1 | HYDROXY SUBSTITUTED THIENO PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-03 | — | — | WO | claimed |
| US-20090298794-A1 | HYDROXY SUBSTITUTED THIENO PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-03 | — | — | US | claimed |
| EP-3954370-B1 | ANTI-FUNGAL AGENT | SEREN PHARMACEUTICALS INC (JP) | 2024-05-29 | — | — | EP | disclosed |
| CN-114126609-B | Novel therapeutic agent for prototheca | 株式会社赛轮制药 | 2024-01-02 | — | — | CN | disclosed |
| US-11667733-B2 | Polyvinyl esters and methods related thereto | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-06-06 | — | — | US | disclosed |
| EP-3998109-A1 | NOVEL THERAPEUTIC AGENT FOR PROTOTHECA DISEASE | Seren Pharmaceuticals Inc. (JP) | 2022-05-18 | — | — | EP | disclosed |
| US-20220142987-A1 | ANTI-FUNGAL AGENT | SEREN PHARMACEUTICALS INC. (JP) | 2022-05-12 | — | — | US | disclosed |
| CN-114126609-A | Novel therapeutic agent for prototheca disease | 株式会社赛轮制药 | 2022-03-01 | — | — | CN | disclosed |
| EP-3954370-A1 | ANTI-FUNGAL AGENT | Seren Pharmaceuticals Inc. (JP) | 2022-02-16 | — | — | EP | disclosed |
| US-4963681-A | Process for synthesis of aminomethylene phosphonoalkylphosphinates | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1990-10-16 | — | — | US | disclosed |
| US-4945158-A | CONTROL BLOOD GLUCOSE LEVEL BY REGULATING ENZYME ACTIVITY | AMERICAN CYANAMID COMPANY (US) | 1990-07-31 | — | — | US | disclosed |
| US-4943629-A | HYPOGLYCEMIC AGENTS; ENZYME STIMULATORS, INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1990-07-24 | — | — | US | disclosed |
| EP-0372157-A1 | Antidiabetic phosphonates | AMERICAN CYANAMID COMPANY (US) | 1990-06-13 | — | — | EP | disclosed |
| EP-0354322-A2 | Antidiabetic alpha-substituted phosphonates | AMERICAN CYANAMID COMPANY (US) | 1990-02-14 | — | — | EP | disclosed |
| EP-0354323-A2 | Antidiabetic phosphates | AMERICAN CYANAMID COMPANY (US) | 1990-02-14 | — | — | EP | disclosed |
| US-4041002-A | A POLYACETAL, A LUBRICANT, AND AN ETHYLENE-VINYL ACETATE COPOLYMER; WEAR RESISTANT | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142987-A1 | ANTI-FUNGAL AGENT | ERG28, CYP51A1, GANAB | LMNA 3834/4885MEN1 2324/4885CYP1A2 328/4885 |
| US-20090298794-A1 | HYDROXY SUBSTITUTED THIENO PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MC1R, MCHR2 | LMNA 4780/4885MEN1 498/4885CYP1A2 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.